System ONE-M installed at leading university hospital in Sweden for NF1 study

A System ONE-M is now installed at the Department of Dermatology and Venereology at Sahlgrenska University Hospital in Gothenburg. The team there is led by professor Sirkku Peltonen, who is one of the world’s leading capacities in treating patients with the genetic tumor syndrome Neurofibromatosis Type 1 (NF1).

NF1 is among the most common single-gene inherited conditions worldwide. Almost all patients with the condition suffer from various degrees of tumors in the skin, called cutaneous neurofibromas. These can number in the hundreds to thousands on a given individual, and while the tumors themselves are mostly benign, they are socially debilitating, painful and impede activities of daily living for those affected.

Despite the remarkable prevalence of skin tumors in people with NF1, and their documented negative influence on quality of life, current treatment is limited to surgical or laser removal. These both have well-known problems of pain during treatment, slow healing, potential infection, dyspigmentation and scarring.

The group in Gothenburg is therefore now all set for the coming clinical investigation on non-invasive removal/reduction of these tumors. It is our hope that the HIFU method can remove the tumors with a non-invasive and significantly less painful procedure, that at the same time effectively eliminates the regular side effects of scarring and dyspigmentation.

Read more about the coming trial here